These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 39012325)

  • 1. A Modern Curriculum for Training Scientists in Model-Informed Drug Development: Progress Report on FDA Grant to Train Regulatory Scientists.
    Barrett JS; Romero K; Rayner C; Gastonguay M; Pillai GC; Tannenbaum S; Kern S; Selich M; Francisco D
    Clin Pharmacol Ther; 2024 Aug; 116(2):289-294. PubMed ID: 39012325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review: Role of Model-Informed Drug Development Approaches in the Lifecycle of Drug Development and Regulatory Decision-Making.
    Madabushi R; Seo P; Zhao L; Tegenge M; Zhu H
    Pharm Res; 2022 Aug; 39(8):1669-1680. PubMed ID: 35552984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Considerations for Industry-Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program.
    Galluppi GR; Ahamadi M; Bhattacharya S; Budha N; Gheyas F; Li CC; Chen Y; Dosne AG; Kristensen NR; Magee M; Samtani MN; Sinha V; Taskar K; Upreti VV; Yang J; Cook J
    Clin Pharmacol Ther; 2024 Aug; 116(2):282-288. PubMed ID: 38519861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Model-Informed Drug Development for Anti-Infectives: State of the Art and Future.
    Rayner CR; Smith PF; Andes D; Andrews K; Derendorf H; Friberg LE; Hanna D; Lepak A; Mills E; Polasek TM; Roberts JA; Schuck V; Shelton MJ; Wesche D; Rowland-Yeo K
    Clin Pharmacol Ther; 2021 Apr; 109(4):867-891. PubMed ID: 33555032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perspective on model-informed drug development.
    Lesko LJ
    CPT Pharmacometrics Syst Pharmacol; 2021 Oct; 10(10):1127-1129. PubMed ID: 34404115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Poisoned Patients: Implementing a Blended Toxicology Curriculum for Emergency Medicine Residents.
    Dwyer M; Stobart-Gallagher M; Kilpatrick J; O'Connell A
    J Educ Teach Emerg Med; 2022 Apr; 7(2):C1-C32. PubMed ID: 37465448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Model-informed drug development in pediatric, pregnancy and geriatric drug development: States of the art and future.
    Wu YE; Zheng YY; Li QY; Yao BF; Cao J; Liu HX; Hao GX; van den Anker J; Zheng Y; Zhao W
    Adv Drug Deliv Rev; 2024 Aug; 211():115364. PubMed ID: 38936664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transforming Evidence Generation for Drug Label Changes: A Case Study.
    Desborough L; Jaffe K; Hanna J; Ulloa J; Kaiserman K
    Ann Biomed Eng; 2023 Jan; 51(1):137-149. PubMed ID: 36070049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An AI Approach to Generating MIDD Assets Across the Drug Development Continuum.
    Barrett JS; Goyal RK; Gobburu J; Baran S; Varshney J
    AAPS J; 2023 Jul; 25(4):70. PubMed ID: 37430126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transforming the Future of Surgeon-Scientists.
    Ladner DP; Goldstein AM; Billiar TR; Cameron AM; Carpizo DR; Chu DI; Coopersmith CM; DeMatteo RP; Feng S; Gallagher KA; Gillanders WE; Lal BK; Lipshutz GS; Liu A; Maier RV; Mittendorf EA; Morris AM; Sicklick JK; Velazquez OC; Whitson BA; Wilke LG; Yoon SS; Zeiger MA; Farmer DL; Hwang ES;
    Ann Surg; 2024 Feb; 279(2):231-239. PubMed ID: 37916404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opportunities and challenges for applying model-informed drug development approaches to gene therapies.
    Belov A; Schultz K; Forshee R; Tegenge MA
    CPT Pharmacometrics Syst Pharmacol; 2021 Apr; 10(4):286-290. PubMed ID: 33608998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report.
    Mackie C; Arora S; Seo P; Moody R; Rege B; Pepin X; Heimbach T; Tannergren C; Mitra A; Suarez-Sharp S; Borges LN; Kijima S; Kotzagiorgis E; Malamatari M; Veerasingham S; Polli JE; Rullo G
    Mol Pharm; 2024 May; 21(5):2065-2080. PubMed ID: 38600804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Industry Perspective on Using MIDD for Pediatric Studies Requiring Integration of Ontogeny.
    Corriol-Rohou S; Cheung SYA
    J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S112-S119. PubMed ID: 31502694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A structured curriculum supporting biomedical trainees' transition into independent academic positions and early career success.
    Perez-Oquendo M; Romano G; Farris DP; Gandhi V; Wistuba II; Tillman RE; Udan R; Mangahas P; Soundararajan R
    BMC Med Educ; 2024 Apr; 24(1):379. PubMed ID: 38589919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consideration of a Credibility Assessment Framework in Model-Informed Drug Development: Potential Application to Physiologically-Based Pharmacokinetic Modeling and Simulation.
    Kuemmel C; Yang Y; Zhang X; Florian J; Zhu H; Tegenge M; Huang SM; Wang Y; Morrison T; Zineh I
    CPT Pharmacometrics Syst Pharmacol; 2020 Jan; 9(1):21-28. PubMed ID: 31652029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities.
    Al-Huniti N; Feng Y; Yu JJ; Lu Z; Nagase M; Zhou D; Sheng J
    CPT Pharmacometrics Syst Pharmacol; 2020 Aug; 9(8):419-427. PubMed ID: 32589767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of Model-Informed Drug Development in Dose Selection and Optimization for siRNA Therapies.
    Yuan Y; Li L; Earp J; Ma L; Bhattaram VA; Sharma V; Tong A; Wang Y; Liu J; Zhu H
    J Clin Pharmacol; 2024 Jul; 64(7):799-809. PubMed ID: 38426370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissolution and Translational Modeling Strategies Enabling Patient-Centric Drug Product Development: the M-CERSI Workshop Summary Report.
    Abend A; Heimbach T; Cohen M; Kesisoglou F; Pepin X; Suarez-Sharp S
    AAPS J; 2018 Apr; 20(3):60. PubMed ID: 29633092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unlocking the eHealth professionals' career pathways: A case of Gulf Cooperation Council countries.
    Zakaria N; Zakaria N; Alnobani O; AlMalki M; El-Hassan O; Alhefzi MI; Househ M; Jamal A
    Int J Med Inform; 2023 Feb; 170():104914. PubMed ID: 36521421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.